Piper Sandler analyst Biren Amin initiates coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral rating and announces Price Target of $46.
Piper Sandler Initiates Coverage On Apellis Pharmaceuticals With Neutral Rating, Announces Price Target of $46
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.